Cordycepin Suppresses Expression of Diabetes Regulating Genes by Inhibition of Lipopolysaccharide-induced Inflammation in Macrophages

Seulmee Shin1, Sungwon Lee1, Jeonghak Kwon1, Sunhee Moon1, Seungjeong Lee2, Chong-Kil Lee2, Kyunghae Cho3, Nam-Joo Ha1 and Kyungjae Kim1*

1College of Pharmacy, Sahmyook University, Seoul, 2College of Pharmacy, Chungbuk University, Cheongju, 3Department of Biology, Seoul Women’s University, Seoul, Korea

Background: It has been recently noticed that type 2 diabetes (T2D), one of the most common metabolic diseases, causes a chronic low-grade inflammation and activation of the innate immune system that are closely involved in the pathogenesis of T2D. Cordyceps militaris, a traditional medicinal mushroom, produces a component compound, cordycepin (3’-deoxyadenosine). Cordycepin has been known to have many pharmacological activities including immunological stimulating, anti-cancer, and anti-infection activities. The molecular mechanisms of cordycepin in T2D are not clear. In the present study, we tested the role of cordycepin on the anti-diabetic effect and anti-inflammatory cascades in LPS-stimulated RAW 264.7 cells. Methods: We confirmed the levels of diabetes regulating genes mRNA and protein of cytokines through RT-PCR and western blot analysis and followed by FACS analysis for the surface molecules. Results: Cordycepin inhibited the production of NO and pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α in LPS-activated macrophages via suppressing protein expression of pro-inflammatory mediators. T2D regulating genes such as 11β-HSD1 and PPAR γ were decreased as well as expression of co-stimulatory molecules such as ICAM-1 and B7-1/-2 were also decreased with the increment of its concentration. In accordance with suppressed pro-inflammatory cytokine production lead to inhibition of diabetic regulating genes in activated macrophages. Cordycepin suppressed NF-κB activation in LPS-activated macrophages. Conclusion: Based on these observations, cordycepin suppressed T2D regulating genes through the inactivation of NF-κB dependent inflammatory responses and suggesting that cordycepin will provide potential use as an immunomodulatory agent for treating immunological diseases. [Immune Network 2009;9(3):98-105]

INTRODUCTION

Obesity is the most common metabolic disease in the industrial world (1). The prevalence of obesity is increasing at an alarming rate along with its associated morbidities, such as atherosclerosis and type 2 diabetes (2). Diabetes mellitus is a metabolic disorder of the endocrine system that is found in all parts of the world and is rapidly increasing in most parts of the world (3).

Type 2 diabetes mellitus, non-insulin-dependent diabetes mellitus (NIDDM), accounts for more than 90% of diabetes patients. Insulin resistance in peripheral tissues leads to compensatory hyperinsulinemia, followed by β-cell failure, leading first to prandial and later to overt fasting hyperglycemia (4). Recent studies have indicated that obesity is associated with a chronic inflammation state, suggesting that inflammation is a potential mechanism by which obesity leads to insulin resistance (5). The authors reported that adipocytes, especially in the obese, secrete a number of pro-inflammatory cytokines, some of which have been shown to directly inhibit insulin signaling. Adipocytokines probably act through master pro-inflammatory regulators, such as those of the NF-κB and JNK/AP-1 signaling pathways to modulate the expression of genes coding for many inflammatory proteins and to alter in-

Received on April 13, 2009. Revised on April 27, 2009. Accepted on May 4, 2009.
*Corresponding Author. Tel: 82-2-3399-1601; Fax: 82-2-3399-1617; E-mail: kimkj@syu.ac.kr

Keywords: cordycepin, type 2 diabetes, pro-inflammatory cytokines, immunomodulator
Cordycepin Suppresses Expression of Diabetes Regulating Genes by Inhibition of Inflammation
Seulmee Shin, et al.

Figure 1. Chemical structure of cordycepin.

Macrophages, which are a type of differentiated tissue cell that originate as blood monocytes, play an important role in immune and allergic reactions as well as in inflammation (6). These cells have several functions including the killing and removal of pathogenic microbes and the processing and presentation of antigens ingested by lymphocytes (7).

Cordyceps militaris is known as the rare Chinese caterpillar fungus (8) and has benefits to the human body including the circulatory, immune, respiratory, and glandular systems. Cordycepin (Fig. 1), 3'-deoxyadenosine, is a major component of cordyceps militaris and a derivative of the nucleoside adenosine only differing from the latter by the absence of oxygen in the 3' position of its ribose entity (9). Cordycepin has been studied for anti-tumor (10), anti-inflammatory (11), anti-diabetic (12), and renoprotective effects (13). Even though cordycepin demonstrates a number of pharmacological properties, further studies are necessary to address these pharmacological differences.

The manner by which macrophages induce insulin resistance in inflammatory responses has not been established, as yet. Macrophages secrete factors induce inflammation in adipose tissue and influence insulin sensitivity, but the specific factors involved, and mechanisms by which they exert these effects, remain unknown. In this study, we tested the role of cordycepin on the NF-κB-dependent inflammation cascades and inhibition of diabetes regulating genes in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells.

MATERIALS AND METHODS

Reagents
Cordycepin and lipopolysaccharide (LPS) were purchased from Sigma (St. Louis, USA). The cell culture media DMEM, antibiotic-penicillin/streptomycin solution and fetal bovine serum (HyClone, Logan, USA) were used for the cell culture.

Cell culture
Murine macrophages cell line (RAW 264.7) was obtained from the American Type Culture Collection (ATCC). Cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented with high glucose, L-glutamine, 110 mg/L sodium pyruvate, 10% fetal bovine serum (FBS), and 1% (v/v) penicillin (10,000 U/ml)/streptomycin (10,000 U/ml) (P/S). The cells were stimulated with LPS (100 ng/ml) in the presence of cordycepin for 24 hr at a concentration 2×10^5 cells/well/200 μl of media on 96-well plates for the NO assay.

MTT assay for cell viability
A commercially-available cell viability assay was employed to evaluate the cytotoxic effect of cordycepin using thiazolyl blue tetrazolium bromide (Sigma, St. Louis, USA). RAW264.7 cells (2×10^5 cells/well) were plated with various concentrations of cordycepin in 96-well microtiter plates (Nunc, Roskilde, Denmark) and were then cultured overnight at 37°C in a 5% CO2 incubator. Afterwards, 50 μl of MTT solution was added to each well, and the cells were then cultured for 4 hrs at 37°C in a 5% CO2 incubator. 100 μl of solubilized solution were added to each well, The plate was allowed to stand overnight in the incubator after evaluation for complete solubilization of the purple formazan crystals and the measurement of the optical density (OD) at 560 nm by a microplate reader (Molecular Devices corporation, Sunnyvale, USA).

Measurement of NO content
To assay the total production of NO, 100 μl of each culture supernatant were incubated at room temperature for 10 min with 100 μl of Griess reagent (stock-I: 0.2% N-(1-naphthyl) ethylenediamine-HCl, stock-II: 2% sulfanilamide in 5% H2PO4). The O.D values of samples were read at 540 nm. A standard curve using NaNO2 was then used to calculate the NO2− concentration.

Isolation of total RNA and RT-PCR
Total RNA was extracted from RAW 264.7 cells using the RNeasy Mini kit (QIAGEN, USA) in an RNase-free environment, RNA was quantified by reading the absorbance at 260 nm as previously described (14). The reverse transcription of 1 μg RNA was carried out using M-MLV reverse transcriptase (Promega, USA), oligo (dT) 16 primer, dNTP (0.5 μM) and 1 U RNase inhibitor. After incubation at 65°C for 5 min and
37°C for 60 min, M-MLV reverse transcriptase was inactivated by heating at 70°C for 15 min. The polymerase chain reaction (PCR) was performed in 50 mM KCl, 10 mM Tris-HCl (pH 8.3), 1.5 mM MgCl₂ and 2.5 mM dNTPs with 5 units of Taq DNA polymerase and 10 pM of each primer set for 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), peroxisome proliferators-activated receptor γ (PPARγ), and regulated upon activation normal T-cell expressed and secreted (RANTES). The cDNA was amplified by 35 cycles of denaturing at 94°C for 45 s, annealing at 62°C for 45 s, and extension at 72°C for 1 min. The PCR products were electrophoresed on a 1.5% agarose gel and stained with ethidium bromide. The primers used were 5′ CAAGGGCGGGAAAGCTCATGG 3′ (forward) and 5′ GGAGGAGATGACGGCAATGC 3′ (reverse) for 11β-HSD1, 5′ ATCATCCTCACTGCAGCCGC 3′ (forward) and 5′ CACACTTGGCGGGCTTCCTCG 3′ (reverse) for RANTES, 5′ GAGCCTGTTGAGACCAACAGC 3′ (forward) and 5′ GATTCGAGGT-TGGTGGGGC 3′ (reverse) for PPARγ, and 5′ GGGAGGAGAGGA-TGGGCGGAGT 3′ (reverse) for β-actin. β-actin was used as an internal control.

Preparation of nuclear extracts
After culture the cells were collected and washed twice with cold PBS, resuspended in hypotonic buffer (10 mM HEPES, pH 7.9, 10 mM KCl, 1.5 mM MgCl₂, 0.2 mM PMSF, 0.5 mM DTT, 10 μg/ml aprotinin). After 15 min incubation on ice, the cells were lysed by the addition of 0.1% NP-40 and vigorous vortexing for 1 min. The nuclei were pelleted by centrifugation at 12,000×g for 1 min at 4°C and resuspended in high salt buffer (20 mM HEPES, pH 7.9, 25% glycerol, 400 mM KCl, 1.5 mM MgCl₂, 0.2 mM EDTA, 0.5 mM DTT, 1 mM NaF, 1 mM sodium orthovanadate). The supernatant fluid was stored in aliquots at −70°C.

Western blot analysis
RAW 264.7 cells were washed with phosphate-buffered saline (PBS) and lysed by lysis buffer (1% SDS, 1.0 mM sodium vanadate, 10 mM Tris-Cl buffer, pH 7.4) for 5 min. Protein concentration was measured using the BCA protein assay. An equal amount of protein from each sample was separated by 10% SDS-polyacrylamide gel and transferred to nitrocellulose membranes. The membranes were blocked with 5% skim milk in PBS solution for 1 hr. They were then incubated with anti-IL-1β, anti-IL-6, anti-TNF-α, anti-iNOS, anti-COX-2, and anti-IFN-γ monoclonal antibody for 2 hrs and washed 3 times with PBST. After incubation with alkaline phosphatase-labeled secondary antibody for 2 hrs, the bands were visualized using a Western Blot Kit with alkaline phosphatase substrate (Vector, Burlingame, USA).

Flow cytometry
RAW 264.7 cells (1×10⁶ cells/ml) were cultured in Petri-dishes. The cells were treated with various concentration of cordycepin (10, 20, 40 μg/ml) in the presence of LPS (100 ng/ml). The dishes were incubated at 37°C for 24 hrs in humidified 5% CO₂ incubator under standard conditions. The cells washed with PBS. The washed cells blocked with staining buffer containing 10% normal mouse serum (NMS) for 20 min on ice. The blocked cells were incubated with co-stimulatory molecules such as ICAM-1, B7-1 and B7-2 antibody for 20 min on ice. The incubated cells were washed with staining buffer 3 times. The washed cells fixed by 1% paraformaldehyde in PBS. The fixed cells were measured by flow cytometry (Beckman coulter, Brea, USA).

Data analysis
Data are expressed as mean±standard deviation. Statistical
Cordycepin Suppresses Expression of Diabetes Regulating Genes by Inhibition of Inflammation
Seulmee Shin, et al.

Figure 3. Effect of cordycepin on the expression of T2D regulating genes in RAW 264.7 cells. Levels of 11β-HSD1, RANTES, and PPARγ mRNA in RAW 264.7. Cells were incubated with various concentrations of cordycepin in the presence of LPS (100 ng/ml) for 24 hrs. The mRNA levels of T2D regulating genes were determined by RT-PCR analysis. β-actin was used as a control.

Figure 4. Effect of cordycepin on the expression of pro-inflammatory cytokines (A) and related proteins (B) in RAW 264.7 cells. Levels of IL-1β, IL-6, and TNF-α (A) and i-NOS and COX-2 (B) in RAW 264.7 cells. Cells were incubated with various concentrations of cordycepin in the presence of LPS (100 ng/ml) for 24 hrs. Protein (20 μg) from each sample was resolved in 8~12% SDS-PAGE and then analyzed by Western blotting. β-actin was used as a control.

RESULTS

Effect of cordycepin on cell viability
To rule out the toxic effect of cordycepin, we tested its effect on the viability of RAW 264.7 by MTT assay. The exposure of cells to cordycepin at 5~40 μg/ml for 24 hr showed no significant adverse effect on the cell viability versus the untreated control (data not shown).

Reduction of NO production in LPS-stimulated RAW 264.7 by cordycepin
In an effort to investigate the effect of cordycepin, we first confirmed whether cordycepin inhibits NO production in activated macrophages. The macrophages did not release NO in response to the medium alone; LPS (100 ng/ml) was used as a positive control for macrophage activation (Fig. 2). When various concentration of cordycepin (5, 10, 20, 40 μg/ml) were added to the culture media in the presence of LPS (100 ng/ml) at the time of cell stimulation (18 hrs), NO production was decreased in a cordycepin concentration-dependent manner.

Inhibition the gene expression of T2D regulating protein and chemokine by cordycepin
To further investigate to important role of cordycepin on T2D,
murine macrophage cells with cordycepin (5~40 μg/ml) in the presence of LPS (100 ng/ml) for 24 hrs decreased T2D regulating genes. As shown in Fig. 3, cordycepin suppressed 11β-HSD1, RANTES, and PPARγ expression dose-dependently.

**Effect of cordycepin on pro-inflammatory cytokines and related proteins**

We determined the intracellular levels of pro-inflammatory cytokines, and related proteins by western blot analysis, showing that cordycepin decreased IL-1β, IL-6, TNF-α, iNOS, and COX-2 in a dose-dependent manner (Fig. 4).

**Regulated the surface expression levels of co-stimulatory molecules**

The RAW 264.7 cell surface expression of ICAM-1, B7-1, and B7-2 was examined by flow cytometry. As shown in Fig. 5, cordycepin inhibited cell surface molecules such as ICAM-1, B7-1, and B7-2 in a dose-dependent manner. LPS-stimulated RAW 264.7 treated with a high concentration of cordycepin (40 μg/ml) had a greater reduction than other concentration.

**Suppressed NF-κB activation by cordycepin**

To investigate whether cordycepin could affect nuclear translocation of NF-κB, western blot analysis for NF-κB p65 was carried out with cell lysate in macrophages (Fig. 6). Amount of NF-κB p65 was markedly increased upon exposure to LPS alone, but cordycepin decreased NF-κB p65.

**DISCUSSION**

The data presented in this paper indicated that cordycepin can exert significant anti-diabetic effects on macrophage-mediated immune responses. The present study demonstrated that cordycepin suppressed NO generation, cytokine (IL-1β, IL-6, and TNF-α) expression, and co-stimulatory molecules in RAW 264.7 cells. M1 macrophages exposed to the classic activation signals IFN-γ and LPS express opsonic receptors,
whereas M2 macrophages are characterized by abundant levels of non-opsonic receptors (15). Inflammation is a complex process involving numerous mediators of cellular and plasma origins. M1 macrophages fuse their lysosomes more efficiently to phagosomes, exposing intracellular or recently ingested extracellular microbes to a variety of microbicioclidal lysosomal enzymes. M1 macrophages also produce oxygen radicals and NO, both of which have potent antimicrobial activity.

Arginine metabolism is characterized by high levels of iNOS in M1 macrophages, whereas the arginase pathway predominates in M2 polarized macrophages. NO is synthesized via the oxidation of arginine by a family of NOS and plays a vital role in regulating physiological processes, such as blood vessel tone and neurotransmission, as well as in host defense and immunity (16,17). However, increasing evidence indicates that NOS plays a complex role in modulating inflammatory response (18). Among these cytokines, IL-1β, IL-6, and TNF-α, have attracted more attention in that they can be localized to the infected tissue, manifested systemically throughout the body and cause vasodilation as well as symptoms of inflammation, such as redness, swelling, heat, and pain (19).

Cordycepin down-regulated the expression of pro-inflammatory molecules likewise NO in LPS-stimulated RAW 264.7 cells (Fig. 2) and when we examined the morphological changes that took place in macrophages treated with cordycepin and LPS, cells treated with LPS and low concentrations of cordycepin (5~10 μg/ml) were similar those exposed to LPS alone. However, cells treated with high concentration of cordycepin (40 μg/ml) in combination with LPS were smoother than those treated with LPS alone (data not shown). Also it inhibited the activation of pro-inflammatory cytokines and related proteins in both of the LPS-activated cell types (Fig. 4).

Macrophages secreted anti-inflammatory cytokines by cordycepin, it differentiate M2 macrophages, M2 macrophages are generally characterized by low production of pro-inflammatory cytokines and high expression of scavenger receptors (15). Cordycepin increased TG accumulation in macrophages (Supplementary Fig. 1). It indicated that M2 macrophages uptake TG from circulation, then are used for fuel (20).

Expression of cytokines requires the activation of NF-κB, NF-κB, a nuclear transcription factor, regulates the expression of various genes, including IL-1β, iNOS, and COX-2 that play critical roles in apoptosis and autoimmune diseases. Its activation requires phosphorylation of IκB, by which lead IκB to ubiquitination and degradation. As shown in Fig. 6, cordycepin decreased pro-inflammatory mediators via suppression of NF-κB activation in murine macrophages.

Growing evidence has pointed to a correlative and causative relationship between inflammation and insulin resistance. The pro-inflammatory cytokines such as TNF-α and IL-6 have been demonstrated to mediated insulin resistance as a result of obesity in many rodent obesity models (21,22). TNF-α was overexpressed in white adipose tissue (WAT) in obese an insulin-resistance states; mice lacking the TNF-α ligand or the p55 TNF receptor were partially protected from obesity-induced insulin resistance (23).

Increasingly, insulin resistance has been recognized as the integral feature of the so-called metabolic syndrome, which includes glucose intolerance, insulin resistance, obesity, hypertriglyceridemia, hypertension, and accelerated atherosclerosis (24).

Glucocorticoids regulate adipocyte differentiation, function and distribution, and in excess cause visceral fat obesity and convergence of metabolic disease (25). Glucocorticoid receptor (GR) is controlled by isozymes of 11β-HSD. Although two isoforms have been identified, it is 11β-HSD1 that has attracted attention with respect to therapeutic inhibition. 11β-HSD1 is a bidirectional enzyme that resides within the endoplasmic reticulum and is widely expression in many glucocorticoid target tissues including liver, adipose tissue where it acts locally to regenerate active cortisol from inactive cortisone and thereby amplify GR activation (26).

RANTES is increased in WAT in the setting of murine and human obesity. Both mRNA and protein levels of RANTES were increased in a gender-dependent fashion in WAT of obesity. RANTES levels were particularly elevated in male mice in the stromal/vascular fraction of WAT as compared with its adipocyte fraction. In addition, monoclonal antibodies directed against RANTES reduced T-cell chemotaxis induced by media conditioned by WAT isolated from obese male mice. These findings underscore the role of RANTES-induced T-cell chemotaxis by WAT in obesity and suggest an opportunity for pharmacological interventions (27).

The transcription factor PPAR is a member of steroid receptor superfamily and has three subtypes named α, δ/β, γ (28). Specially, PPARγ is characterized originally as a key regulation of adipocyte differentiation and lipid metabolism, And it has been shown in macrophage foam cells in athero-
sclerotic plaques (29).

As shown in Fig. 3, cordycepin decreased diabetes regulating genes such as 11β-HSD1, RANTES, and PPARγ in activated macrophages.

IL-1 receptor antagonist (IL-1ra) is a antagonist to the pro-inflammatory cytokine IL-1 receptor, anti-inflammatory cytokine, and it is commonly thought to play an important role in the regulation of inflammatory responses, as corroborated by the enhanced sensitivity of IL-1ra knock-out mice to septic shock and their predisposition to the spontaneous development of inflammatory disorders (30,31). IL-1ra mRNA may contribute to regulation of IL-1ra synthesis that another mechanism may involve inefficient functioning of polyadenylation determinants present in the distal portion of the IL-1ra 3’- untranslated region (3’-UTR) (32).

Cordycepin is an inhibitor of transcription and polyadenylation (33), so that gene expression of IL-1ra in our data remained unprocessed (data not shown).

Intracellular adhesion molecules (ICAMs), ICAM-1, ICAM-2 and ICAM-3, are cell surface ligands for leukocyte integrins. They are crucial in the binding of lymphocytes and other leukocytes to certain cells including antigen-presenting cells (APCs). Cordycepin consistently suppressed expression of ICAM-1 surface molecule in macrophages (Fig. 5A). The B7 family plays an important role as a co-stimulatory factor in APCs, Cordycepin treatment had another major effect on co-stimulatory molecules B7-1/-2 by strongly down-regulating the surface levels of B7-1/-2 molecules in macrophage cells (Fig. 5B, C). All these molecules have been described to be of major importance in APC function (34,35).

In conclusion, we have demonstrated that cordycepin possessed anti-inflammatory and anti-diabetic effects on macrophages. Our findings are supported by inhibitory activity of cordycepin on the NF-κB pathway and other bioactive substances, as well as inhibited expression of diabetes regulating genes.

ACKNOWLEDGEMENTS

This paper was supported by the Sahmyook University Research fund in 2009.

CONFLICTS OF INTEREST

The authors have no financial conflict of interest,

REFERENCES

1. Hotamisigil G, Arner P, Caro J, Atkinson R, Spiegelman B: Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance, J Clin Invest 95;2409-2415, 1995
2. Ogden C, Carroll M, Curtin L, McDowell M, Tabak C, Flegal K: Prevalence of overweight and obesity in the United States, 1999-2004, Am Med Assoc 295;1549-1555, 2006
3. Li W, Zheng H, Bakuru J, De Kimpe N: Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus. J Ethnopharmacol 92:1-21, 2004
4. DeFronzo R: Pathogenesis of NIDDM, A balanced overview, Diabetes care 15;318-368, 1992
5. sjöholm A, Nyström T: Endothelial inflammation in insulin resistance, The Lancet 365;610-612, 2005
6. Ross JA, Auger MJ, In Burke B, Lewis CE: The biology of the macrophage, In: Burke B, Lewis CE, editors, The macrophage, 2nd ed, Oxford: Oxford Medical Publications: p1-72, 2002
7. Kinne R, Brauer R, Stuhlmueller B, Palombo-Kinne E, Burmester G: Macrophages in rheumatoid arthritis, Arthritis Research 2;189-202, 2000
8. Gai G, Jin S, Wang B, Li Y, Li C: The efficacy of Cordyceps militaris capsules in treatment of chronic bronchitis in comparison with Jinshuibao capsules, Chin J New Drugs 13;169-171, 2004
9. Paterson R: Cordyceps: a traditional Chinese medicine and another fungal therapeutic biofactory? Phytochemistry 69;1469-1495, 2008
10. Yoo H, Shin J, Cho J, Son C, Lee Y, Park S, Cho C: Effects of Cordyceps militaris extract on angiogenesis and tumor growth, Acta Pharmacologica Sinica 25;657-665, 2004
11. Kim H, Shrestha B, Lim S, Yoon D, Chang W, Shin D, Han S, Park S, Park J, Park H: Cordycepin inhibits lipopolysaccharide-induced inflammation by the suppression of NF-kappAB through Akt and p38 inhibition in RAW 264.7 macrophage cells, Eur J Pharmacol 545;192-199, 2006
12. Yun Y, Han S, Lee S, Ko S, Lee C, Ha N, Kim K: Anti-diabetic effects of CCCA, CMESS, and cordycepin from Cordyceps militaris capsules and the immune responses in streptozotocin-induced diabetic mice, Nat Pro Sci 9;291-298, 2003
13. Cho M, Lee D, Kim M, Sung J, Ham S: Antimutagenicity and cytotoxicity of cordycepin isolated from Cordyceps militaris, Food Sci Biotechnol 12;472-475, 2003
14. Majumder N, Dey R, Mathur R, Datta S, Maitra M, Ghosh S, Saha B, Majumdar S: An unusual pro-inflammatory role of interleukin-10 induced by arabinosylated lipoxynibinomannan in murine peritoneal macrophages, Glycoconjugate J 23;675-686, 2006
15. Mantovani A, Sica A, Sozanni S, Allavena P, Vecchi A, Locati M: The chemokine system in diverse forms of macrophage activation and polarization, Trends in immunology 25;677-686, 2004
16. Furthgott R, Cherry P, Zawadzki J, Jothianandan D: Endothelial cells as mediators of vasodilation of arteries, J
Cordycepin Suppresses Expression of Diabetes Regulating Genes by Inhibition of Inflammation
Seulmee Shin, et al.

Cardiovasc Pharmacol 6:336-343, 1984

17. Rausch-Fan X, Matejka M: From plaque formation to periodontal disease, is there a role for nitric oxide? Eur J Clin Invest 38:833-835, 2008

18. Wei X, Charles I, Smith A, Ure J, Feng G, Huang F, Xu D, Muller W, Moncada S, Liew F: Altered immune responses in mice lacking inducible nitric oxide synthase; Nature 375:408-411, 1995

19. Haddad JJ, Safieh-Garabedian B, Saadé NE, Kanaan SA, Land SC: Chemooxygenation (delta pO2/ROS)-dependent release of IL-1 beta, IL-6 and TNF-alpha: evidence of cytokines as oxygen-sensitive mediators in the alveolar epithelium, Cytokine 15:138-147, 2001

20. Moestrup S, Moller H: CD163: a regulated hemoglobin scavenger receptor with a role in the anti-inflammatory response, Annals of Medicine 36:347-354, 2004

21. Hotamisligil G, Shargill N, Spiegelman B: Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance, Science 259:87-91, 1993

22. Rotter V, Nagaev I, Smith U: Interleukin-6 (IL-6) induces Insulin Resistance in 3T3-L1 Adipocytes and Is, Like IL-8 and Tumor Necrosis Factor-alpha, Overexpressed in Human Fat Cells in Insulin-resistant Subjects, J Bio Chem 278:45777-45784, 2003

23. Uysal KT, Wiesbrock SM, Hotamisligil GS: Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity, Endocrinology 130:4829-4982, 1998

24. Xu H, Barnes G, Yang Q, Tan G, Yang D, Chou C, Sole J, Nichols A, Ross J, Tartaglia L: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance, J Clin Invest 112:1821-1830, 2003

25. Bujalska I, Kumar S, Stewart P: Does central obesity reflect Cushings disease in the omentum? Lancet (British edition) 345:1210-1213, 1997

26. Tomlison J, Stewart P: 11β-Hydroxysteroid dehydrogenase type 1 as a therapeutic target in the metabolic syndrome, Drug Discov Today 29:3-6, 2005

27. Wu H, Ghosh S, Perrard X, Feng L, Garcia G, Perrard J, Sweeney J, Peterson L, Chan L, Smith C: T-cell accumulation and regulated on activation, normal T cell expressed secreted upregulation in adipose tissue in obesity, Circulation 115:1029, 2007

28. Issermann I, Green S: Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators, Nature 347:645-650, 1990

29. Marx N, Sukhova G, Murphy C, Libby P, Plutzky J: Macrophages in human atheroma contain pparγ differentiation-dependent peroxisomal proliferator-activated receptor γ (PPARγ) expression and reduction of MMP-9 activity through PPARγ activation in mononuclear phagocytes in vitro, ASIP 153:17-23, 1998

30. Nicklin M, Hughes D, Barton J, Ure J, Duff G: Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene, J Exp Med 191:309-312, 2000

31. Horai R, Saito S, Taritsuki H, Nakae S, Sudo K, Okahara A, Ikuse T, Asano M, Iwakura Y: Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice, J Exp Med 191:313-320, 2000

32. Yamshchikov V, Mishina M, Cominelli F: A possible role of IL-1ra 3'-untranslated region in modulation of protein production, Cytokine 17S98-107, 2002

33. Beach L, Ross J: Cordycepin, An inhibitor of newly synthesized globin messenger RNA, J Bio Chem 253:2628-2632, 1978

34. Duzzi F, D’aandrea E, Biasi G, De Silvestro G, Gaidano G, Schena M, Tison T, Vianello F, Girolami A, Galgaris-Cappio F: Failure of B cells of chronic lymphocytic leukemia in presenting soluble and alloantigens, Clin Immunol Immunopathol 75:26-32, 1995

35. Deeths MJ, Mescher MF: ICAM-1 and B7-1 provide similar but distinct costimulation for CD8+ T cells, while CD4+ T cells are poorly costimulated by ICAM-1, Eur J Immunol 29:45-53, 1999